Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 10mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 15mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4